13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Javelin Lung 100

    Acronym: 

    ACTRN/NCT /ethics: 

    NCT02576574

    Scientific title: 

    A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer.

    Summary of trial and patient characteristics

    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III Tumour Stream Non-Small Cell Lung Cancer
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date 2015-10-29
    Molecular Target Anticipated End Date 2024-07-26
    Cancer Type Lung & mesothelioma
    Trial Type Treatment
    Phase Phase III
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Non-Small Cell Lung Cancer
    Cancer Stage
    Anticipated Start Date 2015-10-29
    Anticipated End Date 2024-07-26

    Trial Summary

    The purpose of this study is to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in Non-small cell lung cancer (NSCLC) subjects with Programmed death ligand 1+ (PD-L1+) tumors

    Lay Summary

    A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+ Non-small Cell Lung Cancer.

    Sponsor / Cooperative group

    EMD Serono Research & Development Institute, Inc.

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Queen Elizabeth Hospital Sue Yeend Sue.Yeend@sa.gov.au 08 8222 6148 R Roberts-Thomson Recruitment on Hold